http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 10 Jul 2025 10:36:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Viracta+Therapeutics%2C++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/25037460.html si-local-file:///var/storage/secattach/20250710/25037460.html http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Viracta+Therapeutics%2C++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/25037460.html Thu, 10 Jul 2025 10:36:00 -0400 O.00010841 VIRX http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Viracta+Therapeutics%2C++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/25037460.html si-local-file:///var/storage/secattach/20250710/25037460.html http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Viracta+Therapeutics%2C++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/25037460.html Thu, 10 Jul 2025 10:36:00 -0400 O.00010841 VIRX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Viracta+Therapeutics%2C++++++++++++++++++Filed+by%3A+FORWARD+VENTURES+V+LP/24357566.html si-local-file:///var/storage/secattach/20250214/24357566.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Viracta+Therapeutics%2C++++++++++++++++++Filed+by%3A+FORWARD+VENTURES+V+LP/24357566.html Fri, 14 Feb 2025 20:25:00 -0400 O.00010841 VIRX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Viracta+Therapeutics%2C++++++++++++++++++Filed+by%3A+FORWARD+VENTURES+V+LP/24357566.html si-local-file:///var/storage/secattach/20250214/24357566.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Viracta+Therapeutics%2C++++++++++++++++++Filed+by%3A+FORWARD+VENTURES+V+LP/24357566.html Fri, 14 Feb 2025 20:25:00 -0400 O.00010841 VIRX http://www.streetinsider.com/Corporate+News/Viracta+Therapeutics+%28VIRX%29+Announces+Wind+Down+of+Operations/24303460.html <p>Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs.</p><p>The board of directors appointed Craig R. Jalbert, age 63, as the Company’s CEO, President, CFO, Treasurer and Corporate Secretary, and sole member of the board to implement the wind down. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For http://www.streetinsider.com/Corporate+News/Viracta+Therapeutics+%28VIRX%29+Announces+Wind+Down+of+Operations/24303460.html Wed, 05 Feb 2025 17:00:24 -0400 VIRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viracta+Therapeutics%2C+++++For%3A+Feb+03/24303483.html si-local-file:///var/storage/secattach/20250205/24303483.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viracta+Therapeutics%2C+++++For%3A+Feb+03/24303483.html Wed, 05 Feb 2025 17:00:00 -0400 O.00010841 VIRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viracta+Therapeutics%2C+++++For%3A+Feb+03/24303483.html si-local-file:///var/storage/secattach/20250205/24303483.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viracta+Therapeutics%2C+++++For%3A+Feb+03/24303483.html Wed, 05 Feb 2025 17:00:00 -0400 O.00010841 VIRX http://www.streetinsider.com/Press+Releases/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html <p align="left">SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs.</p> <p>The board of directors appointed Craig R. Jalbert, age 63, as the Company’s CEO, President, CFO, Treasurer and Corporate Secretary, and sole member of the board to implement the wind down. Mr. Jalbert has served as a http://www.streetinsider.com/Press+Releases/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html Wed, 05 Feb 2025 17:00:00 -0400 A.50204699 O.00010841 O.00168799 VIRX http://www.streetinsider.com/Press+Releases/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html <p align="left">SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs.</p> <p>The board of directors appointed Craig R. Jalbert, age 63, as the Company’s CEO, President, CFO, Treasurer and Corporate Secretary, and sole member of the board to implement the wind down. Mr. Jalbert has served as a http://www.streetinsider.com/Press+Releases/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html Wed, 05 Feb 2025 17:00:00 -0400 A.50204699 O.00010841 O.00168799 VIRX http://www.streetinsider.com/Press+Releases/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html <p align="left">SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs.</p> <p>The board of directors appointed Craig R. Jalbert, age 63, as the Company’s CEO, President, CFO, Treasurer and Corporate Secretary, and sole member of the board to implement the wind down. Mr. Jalbert has served as a http://www.streetinsider.com/Press+Releases/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html Wed, 05 Feb 2025 17:00:00 -0400 A.50204699 O.00010841 O.00168799 VIRX http://www.streetinsider.com/Press+Releases/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html <p align="left">SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs.</p> <p>The board of directors appointed Craig R. Jalbert, age 63, as the Company’s CEO, President, CFO, Treasurer and Corporate Secretary, and sole member of the board to implement the wind down. Mr. Jalbert has served as a http://www.streetinsider.com/Press+Releases/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html Wed, 05 Feb 2025 17:00:00 -0400 A.50204699 O.00010841 O.00168799 VIRX http://www.streetinsider.com/Globe+Newswire/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html <p align="left">SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs.</p> <p>The board of directors appointed Craig R. Jalbert, age 63, as the Company’s CEO, President, CFO, Treasurer and Corporate Secretary, and sole member of the board to implement the wind down. Mr. Jalbert has served as a http://www.streetinsider.com/Globe+Newswire/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html Wed, 05 Feb 2025 17:00:00 -0400 A.50204699 O.00010841 O.00168799 VIRX http://www.streetinsider.com/Globe+Newswire/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html <p align="left">SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs.</p> <p>The board of directors appointed Craig R. Jalbert, age 63, as the Company’s CEO, President, CFO, Treasurer and Corporate Secretary, and sole member of the board to implement the wind down. Mr. Jalbert has served as a http://www.streetinsider.com/Globe+Newswire/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html Wed, 05 Feb 2025 17:00:00 -0400 A.50204699 O.00010841 O.00168799 VIRX http://www.streetinsider.com/Globe+Newswire/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html <p align="left">SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs.</p> <p>The board of directors appointed Craig R. Jalbert, age 63, as the Company’s CEO, President, CFO, Treasurer and Corporate Secretary, and sole member of the board to implement the wind down. Mr. Jalbert has served as a http://www.streetinsider.com/Globe+Newswire/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html Wed, 05 Feb 2025 17:00:00 -0400 A.50204699 O.00010841 O.00168799 VIRX http://www.streetinsider.com/Globe+Newswire/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html <p align="left">SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs.</p> <p>The board of directors appointed Craig R. Jalbert, age 63, as the Company’s CEO, President, CFO, Treasurer and Corporate Secretary, and sole member of the board to implement the wind down. Mr. Jalbert has served as a http://www.streetinsider.com/Globe+Newswire/Viracta+Therapeutics+Announces+Wind+Down+of+Operations/24303453.html Wed, 05 Feb 2025 17:00:00 -0400 A.50204699 O.00010841 O.00168799 VIRX http://www.streetinsider.com/Downgrades/Rodman+%26+Renshaw+Downgrades+Viracta+Therapeutics+%28VIRX%29+to+Neutral/24146581.html <p>Rodman & Renshaw downgraded Viracta Therapeutics (NASDAQ: VIRX) from Buy to Neutral with a price target of $0.25 (from $3.50).</p> <p>For an analyst ratings summary and ratings history on Viracta Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=VIRX">click here</a>. For more ratings news on Viracta Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=VIRX&amp;type=analyst">click here</a>.</p> <p>Shares of Viracta Therapeutics closed at $0.24 yesterday.</p> http://www.streetinsider.com/Downgrades/Rodman+%26+Renshaw+Downgrades+Viracta+Therapeutics+%28VIRX%29+to+Neutral/24146581.html Fri, 27 Dec 2024 07:03:13 -0400 VIRX http://www.streetinsider.com/Analyst+PT+Change/Rodman+%26+Renshaw+Downgrades+Viracta+Therapeutics+%28VIRX%29+to+Neutral/24146581.html <p>Rodman & Renshaw downgraded Viracta Therapeutics (NASDAQ: VIRX) from Buy to Neutral with a price target of $0.25 (from $3.50).</p> <p>For an analyst ratings summary and ratings history on Viracta Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=VIRX">click here</a>. For more ratings news on Viracta Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=VIRX&amp;type=analyst">click here</a>.</p> <p>Shares of Viracta Therapeutics closed at $0.24 yesterday.</p> http://www.streetinsider.com/Analyst+PT+Change/Rodman+%26+Renshaw+Downgrades+Viracta+Therapeutics+%28VIRX%29+to+Neutral/24146581.html Fri, 27 Dec 2024 07:03:13 -0400 VIRX http://www.streetinsider.com/Corporate+News/Viracta+Therapeutics+%28VIRX%29+Announces+Closure+of+NAVAL-1+Clinical+Trial+and+Exploration+of+Strategic+Alternatives/24145516.html <p>Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives.</p><p>To maximize its cash runway while the Board conducts its review of strategic alternatives, Viracta has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas (the NAVAL-1 trial). The company emphasized that its decision to voluntarily close the trial is not the result of any new safety finding.</p><p>“As we continue to look http://www.streetinsider.com/Corporate+News/Viracta+Therapeutics+%28VIRX%29+Announces+Closure+of+NAVAL-1+Clinical+Trial+and+Exploration+of+Strategic+Alternatives/24145516.html Thu, 26 Dec 2024 16:30:38 -0400 VIRX http://www.streetinsider.com/FDA/Viracta+Therapeutics+%28VIRX%29+Announces+Closure+of+NAVAL-1+Clinical+Trial+and+Exploration+of+Strategic+Alternatives/24145516.html <p>Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives.</p><p>To maximize its cash runway while the Board conducts its review of strategic alternatives, Viracta has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas (the NAVAL-1 trial). The company emphasized that its decision to voluntarily close the trial is not the result of any new safety finding.</p><p>“As we continue to look http://www.streetinsider.com/FDA/Viracta+Therapeutics+%28VIRX%29+Announces+Closure+of+NAVAL-1+Clinical+Trial+and+Exploration+of+Strategic+Alternatives/24145516.html Thu, 26 Dec 2024 16:30:38 -0400 VIRX http://www.streetinsider.com/Mergers+and+Acquisitions/Viracta+Therapeutics+%28VIRX%29+Announces+Closure+of+NAVAL-1+Clinical+Trial+and+Exploration+of+Strategic+Alternatives/24145516.html <p>Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives.</p><p>To maximize its cash runway while the Board conducts its review of strategic alternatives, Viracta has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas (the NAVAL-1 trial). The company emphasized that its decision to voluntarily close the trial is not the result of any new safety finding.</p><p>“As we continue to look http://www.streetinsider.com/Mergers+and+Acquisitions/Viracta+Therapeutics+%28VIRX%29+Announces+Closure+of+NAVAL-1+Clinical+Trial+and+Exploration+of+Strategic+Alternatives/24145516.html Thu, 26 Dec 2024 16:30:38 -0400 VIRX http://www.streetinsider.com/Press+Releases/Viracta+Therapeutics+Announces+Closure+of+NAVAL-1+Clinical+Trial+and+Exploration+of+Strategic+Alternatives/24145506.html <p align="left">SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives.</p> <p>To maximize its cash runway while the Board conducts its review of strategic alternatives, Viracta has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas (the NAVAL-1 trial). The company emphasized that its decision to voluntarily close the trial http://www.streetinsider.com/Press+Releases/Viracta+Therapeutics+Announces+Closure+of+NAVAL-1+Clinical+Trial+and+Exploration+of+Strategic+Alternatives/24145506.html Thu, 26 Dec 2024 16:30:00 -0400 O.00010841 VIRX http://www.streetinsider.com/Press+Releases/Viracta+Therapeutics+Announces+Closure+of+NAVAL-1+Clinical+Trial+and+Exploration+of+Strategic+Alternatives/24145506.html <p align="left">SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives.</p> <p>To maximize its cash runway while the Board conducts its review of strategic alternatives, Viracta has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas (the NAVAL-1 trial). The company emphasized that its decision to voluntarily close the trial http://www.streetinsider.com/Press+Releases/Viracta+Therapeutics+Announces+Closure+of+NAVAL-1+Clinical+Trial+and+Exploration+of+Strategic+Alternatives/24145506.html Thu, 26 Dec 2024 16:30:00 -0400 O.00010841 VIRX http://www.streetinsider.com/Globe+Newswire/Viracta+Therapeutics+Announces+Closure+of+NAVAL-1+Clinical+Trial+and+Exploration+of+Strategic+Alternatives/24145506.html <p align="left">SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives.</p> <p>To maximize its cash runway while the Board conducts its review of strategic alternatives, Viracta has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas (the NAVAL-1 trial). The company emphasized that its decision to voluntarily close the trial http://www.streetinsider.com/Globe+Newswire/Viracta+Therapeutics+Announces+Closure+of+NAVAL-1+Clinical+Trial+and+Exploration+of+Strategic+Alternatives/24145506.html Thu, 26 Dec 2024 16:30:00 -0400 O.00010841 VIRX http://www.streetinsider.com/Globe+Newswire/Viracta+Therapeutics+Announces+Closure+of+NAVAL-1+Clinical+Trial+and+Exploration+of+Strategic+Alternatives/24145506.html <p align="left">SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives.</p> <p>To maximize its cash runway while the Board conducts its review of strategic alternatives, Viracta has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas (the NAVAL-1 trial). The company emphasized that its decision to voluntarily close the trial http://www.streetinsider.com/Globe+Newswire/Viracta+Therapeutics+Announces+Closure+of+NAVAL-1+Clinical+Trial+and+Exploration+of+Strategic+Alternatives/24145506.html Thu, 26 Dec 2024 16:30:00 -0400 O.00010841 VIRX http://www.streetinsider.com/Earnings/Viracta+Therapeutics%2C+Inc.+%28VIRX%29+Reports+In-Line+Q3+EPS/23974800.html <p>Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q3 EPS of ($0.27), in-line with the analyst estimate of ($0.27).</p><p>For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) <a href="http://www.streetinsider.com/ec_earnings.php?q=VIRX">click here</a>.</p> http://www.streetinsider.com/Earnings/Viracta+Therapeutics%2C+Inc.+%28VIRX%29+Reports+In-Line+Q3+EPS/23974800.html Wed, 13 Nov 2024 16:11:43 -0400 VIRX